PDCD1 and melanoma: SAR’245 showed single-agent antitumor activity in the B16F10 melanoma and the CT-26 colonic syngeneic mouse tumor models that was increased in combination with a programmed cell-death protein 1 (PD-1) inhibitory antibody in the CT-26 model (Ma and colleagues; submitted for publication; ref. 14).